Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma

Published:2020 Issue:5 Volume:98 Page:295-302
ISSN:0030-2414
Container-title:Oncology
language:en
Short-container-title:Oncology

Author:

Hiraoka Atsushi^ORCID,Kumada Takashi^ORCID,Tada Toshifumi,Fukunishi Shinya,Atsukawa Masanori,Hirooka Masashi,Tsuji Kunihiko,Ishikawa Toru,Takaguchi Koichi,Kariyama Kazuya,Itobayashi Ei,Tajiri Kazuto^ORCID,Shimada Noritomo,Shibata Hiroshi,Ochi Hironori,Kawata Kazuhito,Toyoda Hidenori,Ohama Hideko,Tsutsui Akemi,Itokawa Norio,Hayama Korenobu,Arai Taeang,Imai Michitaka,Nakamura Shinichiro,Michitaka Kojiro,Hiasa Yoichi,Kudo Masatoshi,

Publisher

S. Karger AG

Subject

Cancer Research,Oncology,General Medicine

Reference28 articles.

1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.

2. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.

3. Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56–66.

4. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–73.

5. Hiraoka A, Kumada T, Kariyama K, Takaguchi K, Itobayashi E, Shimada N, et al. Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: multicenter analysis. Hepatol Res. 2019;49:111–7.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nutritional assessment and following nutritional intervention during drug therapy for patients with hepatobiliary carcinoma;The Japanese Journal of SURGICAL METABOLISM and NUTRITION;2023-12-15

2. Preoperative inflammation and nutrition-based comprehensive biomarker for predicting prognosis in resectable colorectal cancer;Frontiers in Oncology;2023-11-22

3. Association between prognostic nutritional index and peritoneal dialysis discontinuation: a retrospective cohort study;Renal Replacement Therapy;2023-11-07

4. Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib;2023-10-24

5. Prognostic significance of psoas muscle index in male hepatocellular carcinoma patients treated with immune checkpoint inhibitors and tyrosine kinase inhibitors;Human Vaccines & Immunotherapeutics;2023-08